Skip to content

Kaiser Permanente Mid-Atlantic

Does Kaiser Permanente Mid-Atlantic cover Zepbound for Weight Loss?

Yes. Kaiser Permanente Mid-Atlantic covers Zepbound for weight loss with prior authorization if your BMI is 27 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Hmo Exchange Prior Authorization Criteria En

    Kaiser Permanente Mid-Atlantic · PA policy · Employer, ACA Marketplace, and Federal Employee Program

    Effective June 2, 2026. Verified June 5, 2026.

    View PDF Download Original insurer source
  • Employer, ACA Marketplace, and Federal Employee Program: Covered with requirements. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (3 plan types)

Applies to Employer, ACA Marketplace, and Federal Employee Program plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Zepbound for weight loss — BMI 27 to <30 with comorbidity (after semaglutide step therapy)

All of:

  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
  • Age ≥ 18 years
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
  • Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
  • Baseline BMI 27 to <30 kg/m2
  • At least ONE qualifying weight-related comorbidity
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial of qualifying oral weight management medication
  • Documented baseline weight within past 30 days
  • Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI 30 to <35 (after semaglutide step therapy)

All of:

  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
  • Age ≥ 18 years
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
  • Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
  • Baseline BMI 30 to <35 kg/m2
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial of qualifying oral weight management medication
  • Documented baseline weight within past 30 days
  • Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI 35 to <40 (after semaglutide step therapy)

All of:

  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
  • Age ≥ 18 years
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
  • Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
  • Baseline BMI 35 to <40 kg/m2
  • Documented baseline weight within past 30 days
  • Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI ≥40 (after semaglutide step therapy)

All of:

  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
  • Age ≥ 18 years
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
  • Currently enrolled in and/or following a lifestyle intervention program (to begin at or before medication initiation) and will continue lifestyle modifications
  • Baseline BMI ≥40 kg/m2
  • Documented baseline weight within past 30 days
  • Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Documentation to bring

  • Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is an Endocrinologist, Pediatrician, or Weight Management Specialist
  • Patient age documentation (≥18 years)
  • Documented baseline weight within past 30 days
  • Documented baseline BMI
  • Documentation of intolerance, contraindication, or failure to lose/maintain ≥5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
  • Detailed diet and exercise log for past 90-180 days (lifestyle interventions with nutrition and physical activity components)
  • For BMI 27 to <30: documentation of at least one qualifying weight-related comorbidity
  • For BMI 27 to <35: documentation of intolerance, contraindication, or failure to lose/maintain ≥5% body weight after 3-month trial of qualifying oral weight management medication
  • Documentation that Zepbound is not being used in combination with another GLP-1 RA or GIP/GLP-1 RA

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to <27: 3-month x 1 reauthorization only (for deprescribing). If BMI ≥27: 6-month reauthorization. Prior semaglutide step therapy and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members.

Not covered when

  • Combination use with another GIP/GLP-1 RA or GLP-1 RA not permitted

Policy note: Zepbound for weight loss requires prior documented failure/intolerance/contraindication to semaglutide for overweight or obesity (3-month trial at maximum tolerated dose) — this is a GLP-1 RA step-therapy requirement specific to Zepbound. Lifestyle documentation requirement is more specific than Wegovy: detailed diet and exercise log for past 90-180 days required. Age minimum is 18 (vs 12 for Saxenda/Wegovy). The BMI tier criteria from the general weight management section apply to Zepbound as they do to Wegovy and Saxenda, with the additional semaglutide step-therapy layer. Prior oral weight management drug step therapy applies to BMI 27 to <35 tiers.

Policy effective June 2, 2026 · verified June 5, 2026 · source: Hmo Exchange Prior Authorization Criteria En · View policy document (PDF)

Open on its own page →

Questions people ask
Does Kaiser Permanente Mid-Atlantic cover Zepbound?
Yes. Kaiser Permanente Mid-Atlantic covers Zepbound for weight loss with prior authorization if your BMI is 27 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
How long does a Zepbound approval last with Kaiser Permanente Mid-Atlantic?
Weight Loss — Applies to Employer, ACA Marketplace, and Federal Employee Program plans. Initial approval: 6 months. Renewal: every 6 months.
What does Kaiser Permanente Mid-Atlantic require to renew Zepbound?
Weight Loss — Applies to Employer, ACA Marketplace, and Federal Employee Program plans. Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to <27: 3-month x 1 reauthorization only (for deprescribing). If BMI ≥27: 6-month reauthorization. Prior semaglutide step therapy and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members.
How current is this information?
The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Kaiser Permanente Mid-Atlantic: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Elevance Health, Maryland Medicaid, Virginia Medicaid, Alabama Medicaid, California Medicaid, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid

All insurance plans · All medications

Summary of Kaiser Permanente Mid-Atlantic's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.